Recombinant Human Chemokine (C-C motif) Ligand 19, T7-tagged
Cat.No. : | CCL19-154H |
Product Overview : | Recombinant human CCL19 protein, fused to T7-tag at N-terminus, was expressed inE.coliand purifed by conventional chromatography, after refolding of the isolated inclusion bodies in a renaturation buffer.MW = 10.4 kDa (93aa). |
- Specification
- Gene Information
- Related Products
Description : | CCL19 is a small cytokine belonging to the CC chemokine family that is also known as thymus and activation regulated chemokine (TARC). This protein is involved in immunoregulatory and inflammatory processes. It elicits its effects on its target cells by binding to the chemokine receptor chemokine receptor CCR7. It attracts certain cells of the immune system, including dendritic cells and antigen-engaged B cells, CCR7+ effector-memory T-Cells. |
Source : | E.coli. |
Form : | Liquid. In Phosphate Buffered Saline pH7.4 containing 10% glycerol. |
Purity : | > 95% by SDS – PAGE. |
Concentration : | 0.5 mg/ml (determined by Bradford assay). |
Sequences Of Amino Acids : | MASMTGGQQM GRGSHMGTND AEDCCLSVTQ KPIPGYIVRN FHYLLIKDGC RVPAVVFTTL RGRQLCAPPD QPWVERIIQR LQRTSAKMKR RSS. |
Storage : | can be stored at +4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or -70°C. Avoid repeated freezing and thawing cycles. |
Gene Name : | CCL19 chemokine (C-C motif) ligand 19 [ Homo sapiens ] |
Synonyms : | small inducible cytokine A19; exodus-3; CK beta-11; EBI1-ligand chemokine ; CC chemokine ligand 19; beta chemokine exodus-3; small inducible cytokine subfamily A (Cys-Cys), member 19; ELC; CKb11; MIP3B; MIP-3b; SCYA19; MGC34433; CCL19; Macrophage inflammatory protein 3 beta; Short name=MIP-3-beta; EBI1-ligand chemokine;Short name=ELC; Beta chemokine exodus-3; CK beta-11; C-C motif chemokine 19; ELC; MIP3B; SCYA19; Chemokine (C-C motif) Ligand 19 |
Gene ID : | 6363 |
mRNA Refseq : | NM_006274 |
Protein Refseq : | NP_006265 |
MIM : | 602227 |
UniProt ID : | Q99731 |
Chromosome Location : | 9p13 |
Pathway : | Chemokine signaling pathway; Cytokine-cytokine receptor interaction; Signaling by GPCR |
Function : | chemokine activity |
Products Types
◆ Recombinant Protein | ||
CCL19-2893M | Recombinant Mouse CCL19 Protein | +Inquiry |
CCL19-119C | Recombinant Cynomolgus Monkey CCL19 Protein, His (Fc)-Avi-tagged | +Inquiry |
CCL19-4399M | Recombinant Monkey CCL19 Protein | +Inquiry |
Ccl19-4339M | Recombinant Mouse Ccl19 Protein | +Inquiry |
CCL19-013H | Recombinant Human CCL19 Protein | +Inquiry |
◆ Lysates | ||
CCL19-7729HCL | Recombinant Human CCL19 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionThere are still some limitations in the current research on CCL19, such as the lack of in-depth research on its specific mechanism of action and function, and the incomplete understanding of its relationship with diseases. In addition, since CCL19 is a multifunctional protein, regulating it may also have some side effects.
It has a complex relationship with other chemokines or proteins. For example, it binds to the CCR7 receptor, which directs the migration of immune cells. In addition, CCL19 interacts with other chemokines and cytokines to jointly regulate immune responses.
Therapeutic strategies for CCL19 include inhibition of its expression, modulation of its activity, or use of gene therapy. For example, some studies have shown that the use of small molecule inhibitors or antibodies against CCL19 can inhibit its activity and thus treat some CCL19-related diseases. In addition, related diseases can also be treated by regulating the expression level of CCL19.
In order to better understand the role of CCL19 in disease, further in-depth study of its specific mechanism of action and function is needed. In addition, it is also necessary to study the changes in its expression level and activity in different diseases, as well as its relationship with the occurrence and development of diseases. At the same time, it is also necessary to explore the clinical application prospects and effects of the therapeutic strategies that regulate them. This will contribute to the development of more effective treatments to improve outcomes and quality of life for patients with CCL19-related diseases.
CCL19 is mainly involved in the recruitment and activation of immune cells. It is able to exert immune defense by binding to receptors on the cell surface to direct immune cells to migrate to the site of inflammation or infection. In addition, CCL19 is also able to regulate the activation and differentiation of immune cells, affecting the type and intensity of immune responses.
Recent studies have found that CCL19 is also involved in the production and maintenance of lymphatic vessels. These processes have an important impact on the migration of immune cells and the regulation of immune responses, and also provide new ideas for the treatment of some diseases related to CCL19.
Customer Reviews (3)
Write a reviewThe quality of the production is stable, and the batch-to-batch and intra-batch repeatability is good.
CCL19 has a complete range of specifications and is suitable for experiments of different scales.
The preparation is simple and we can do it ourselves.
Ask a Question for All CCL19 Products
Required fields are marked with *
My Review for All CCL19 Products
Required fields are marked with *
Inquiry Basket